Last reviewed · How we verify
NCT07024732
An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration
Phase 1 trial testing PST-611 in Dry Age Related Macular Degeneration in 12 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Eyevensys |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 July 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 June 2026 |
| Sites | 2 locations across France |
Drugs / interventions tested
- PST-611 — full drug profile →
Conditions studied
- Dry Age Related Macular Degeneration — all drugs for Dry Age Related Macular Degeneration →
Sponsor
Eyevensys — full company profile →
Who can join
50 and older, any sex, with Dry Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety and Tolerability
Time frame: Screening to week 16
Ocular and non-ocular adverse events frequency and severity
Sponsor's own description
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07024732
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Eyevensys trials
Trials by the same sponsor.
- NCT04207983 — A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic · Phase 2 · completed
- NCT03308045 — Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07024732 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eyevensys
- Last refreshed: 9 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07024732.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing